The 2022 EULAR / ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome ( HLH / MAS )
Arthritis & Rheumatology · 2023-10 · 75 (10) · 1714-1732
DOI: 10.1002/art.42636 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Arthritis & Rheumatology, online erschienen am 24.07.2023. Verfasst von Bita Shakoory und 30 weiteren Autor:innen. Beteiligte Einrichtung: Translational Autoinflammatory Diseases Section, NIH, Bethesda, Maryland. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Macrophage Activation Syndrome, Physicians. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Objective
Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life‐threatening systemic hyperinflammatory syndromes that can develop in most inflammatory contexts. They can progress rapidly, and early identification and management are critical for preventing organ failure and mortality. This effort aimed to develop evidence‐based and consensus‐based points to consider to assist clinicians in optimising decision‐making in the early stages of diagnosis, treatment and monitoring of HLH/MAS.
Methods
A multinational, multidisciplinary task force of physician experts, including adult and paediatric rheumatologists, haematologist/oncologists, immunologists, infectious disease specialists, intensivists, allied healthcare professionals and patients/parents, formulated relevant research questions and conducted a systematic literature review (SLR). Delphi methodology, informed by SLR results and questionnaires of experts, was used to generate statements aimed at assisting early decision‐making and optimising the initial care of patients with HLH/MAS.
Results
The task force developed 6 overarching statements and 24 specific points to consider relevant to early recognition of HLH/MAS, diagnostic approaches, initial management and monitoring of HLH/MAS. Major themes included the simultaneous need for prompt syndrome recognition, systematic evaluation of underlying contributors, early intervention targeting both hyperinflammation and likely contributors, careful monitoring for progression/complications and expert multidisciplinary assistance.
Conclusion
These 2022 EULAR/American College of Rheumatology points to consider provide up‐to‐date guidance, based on the best available published data and expert opinion. They are meant to help guide the initial evaluation, management and monitoring of patients with HLH/MAS in order to halt disease progression and prevent life‐threatening immunopathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Translational Autoinflammatory Diseases Section, NIH, Bethesda, Maryland.
- Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, and Hematology/Oncology, University of Western Ontario Schulich School of…
- Hematology/Oncology, University of Western Ontario Schulich School of Medicine & Dentistry, London, Ontario, Canada.
- Pediatric Critical Care Medicine, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
- Pediatric Critical Care Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee.
- Pediatrics, University of Western Ontario Schulich School of Medicine & Dentistry, London, Ontario, Canada.
ORCID-Profile: Angelo Ravelli, Edward M Behrens, Randy Q Cron, Lauren A Henderson, Grant Schulert, Erkan Demirkaya, Raphaela Goldbach-Mansky, Fabrizio de Benedetti, Scott W Canna
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- Intramural NIH HHS
- EULAR
- National Institutes of Health
Zitieren
APA
Shakoory, B., Geerlinks, A., Wilejto, M., Kernan, K., Hines, M., Romano, M., Piskin, D., Ravelli, A., Sinha, R., Aletaha, D., Allen, C., Bassiri, H., Behrens, E. M., Carcillo, J., Carl, L., Chatham, W., Cohen, J. I., Cron, R. Q., Drewniak, E., …, & Canna, S. W. (2023). The 2022 EULAR / ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome ( HLH / MAS ). Arthritis & Rheumatology, 75(10), 1714-1732. https://doi.org/10.1002/art.42636
Vancouver
Shakoory B, Geerlinks A, Wilejto M, Kernan K, Hines M, Romano M, et al. The 2022 EULAR / ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome ( HLH / MAS ). Arthritis & Rheumatology. 2023;75(10):1714-1732. doi:10.1002/art.42636
BibTeX
@article{Shakoory2023,
author = {Shakoory, Bita and Geerlinks, Ashley and Wilejto, Marta and Kernan, Kate and Hines, Melissa and Romano, Micol and Piskin, David and Ravelli, Angelo and Sinha, Rashmi and Aletaha, Daniel and Allen, Carl and Bassiri, Hamid and Behrens, Edward M and Carcillo, Joseph and Carl, Linda and Chatham, Winn and Cohen, Jeffrey I and Cron, Randy Q and Drewniak, Erik and Grom, Alexei A and Henderson, Lauren A and Horne, Annacarin and Jordan, Michael B and Nichols, Kim E and Schulert, Grant and Vastert, Sebastiaan and Demirkaya, Erkan and Goldbach-Mansky, Raphaela and de Benedetti, Fabrizio and Marsh, Rebecca A and Canna, Scott W},
title = {The 2022 EULAR / ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome ( HLH / MAS )},
journal = {Arthritis & Rheumatology},
year = {2023},
volume = {75},
number = {10},
pages = {1714--1732},
doi = {10.1002/art.42636}
}
EUVIMED